16 March 2025 in Clinical and Translational Oncology
Background: Despite the success of immune checkpoint inhibitors (ICIs) in metastatic melanoma, many patients fail to derive meaningful benefit, underscoring the urgent need for accessible prognostic biomarkers. The C-reactive protein (CRP)–albumin–lymphocyte (CALLY) index, an immunonutritional index, has shown prognostic value in various cancers. Previous studies indicate that systemic inflammation and nutritional status influence ICI efficacy, suggesting the potential relevance of the CALLY index in metastatic melanoma. This study evaluates the CALLY index’s role in metastatic melanoma patients treated with anti-PD-1 therapy. Methods: This retrospective study analysed 92 patients with metastatic melanoma who were treated with anti-PD-1 monotherapy at Ege University’s Faculty of Medicine between 2015 and 2023. The CALLY index was calculated using the pre-treatment CRP, albumin and lymphocyte levels. Kaplan–Meier analysis was used to estimate survival outcomes, and univariate and multivariate Cox regression models were employed to identify independent prognostic factors. A predictive nomogram incorporating the CALLY index and other significant variables was then developed. Results: The optimal CALLY index cutoff was determined to be 2. Patients with a low CALLY index (≤ 2) had worse median overall survival (OS) and progression-free survival (PFS) when compared with those who had a high CALLY index (> 2) (median OS: 9.6 vs 31.3 months, p < 0.001; median PFS: 3.8 vs 10.6 months, p = 0.001). Multivariate analysis identified the CALLY index, lactate dehydrogenase above the upper limit of normal, Eastern Cooperative Oncology Group score ≥ 2, M1c/M1d staging and acral/mucosal melanoma subtypes to be independent predictors of OS. A nomogram was then constructed based on these factors, yielding a concordance index of 0.705 (95% confidence interval: 0.634–0.776). This model stratified patients into low-, intermediate- and high-risk groups, with the high-risk group showing significantly worse OS than the intermediate- and the low-risk groups (p < 0.001). Conclusion: The CALLY index is a cost-effective and independent prognostic biomarker that can aid in risk stratification and guide treatment decisions in patients with metastatic melanoma receiving anti-PD-1 therapy.
20 December 2024 in Discover Oncology
Immune checkpoint inhibitors (ICIs) have significantly improved the five-year survival rate for advanced melanoma. However, many patients exhibit resistance to ICI therapy. This study evaluated the efficacy and prognostic factors of anti-PD-1 (Group A) and nivolumab–ipilimumab (Group B) therapy in patients with advanced melanoma who were resistant to prior ICI therapy. We conducted a retrospective analysis of 56 patients with advanced melanoma who had previously shown resistance to ICI therapy. In the Group A (who have previously shown resistance to anti-CTLA-4, n = 28), the objective response rate (ORR) was 42.9%, with a disease control rate (DCR) of 53%. In the Group B (previously shown resistance to anti-PD-1, n = 28), the ORR was 17.9%, and the DCR was 25%. The ORR was lower in two subgroups: patients who showed progression or relapse in the the initial radiological assessment of prior ICI therapy (ORR 10.5%) and patients who had previously received ICI in the adjuvant setting (ORR 8.3%). A Royal Marsden Hospital (RMH) score of 2–3 was a predictor of OS in both groups (Group A: HR 3.789, 95% CI 1.356–10.589, p = 0.011; Group B: HR 4.281, 95% CI 1.490–12.300, p = 0.007) and for PFS in the Group B (HR 3.167, 95% CI 1.062–9.442, p = 0.039). Anti-PD-1 therapy demonstrated efficacy following resistance to anti-CTLA-4, whereas combination ICI therapy showed lower response rates in patients resistant to anti-PD-1. Further studies are needed to confirm the RMH scores and other prognostic markers and to evaluate subgroups with lower efficacy of nivolumab-ipilimumab therapy.
21 August 2025 in Clinical and Translational Oncology
17 April 2025 in BMC Psychology
This study sought to translate and validate the Fear of Progression Questionnaire-Short Form (FoP-Q-SF) for use in assessing the FoP among Turkish cancer patients. A sample of 185 cancer patients who were undergoing active treatment at Ege University Oncology Clinic participated in this study. The FoP-Q-SF was translated into Turkish and its psychometric properties were assessed. The questionnaire’s reliability was evaluated using Cronbach’s alpha and McDonald’s omega, while its validity was tested via confirmatory factor analysis (CFA) and correlation with established measures such as the Hospital Anxiety and Depression Scale (HADS) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30). The FoP-Q-SF demonstrated high internal consistency (Cronbach’s alpha = 0.89, McDonald’s omega = 0.89) and a strong unidimensional structure based on CFA (CFI = 0.987, TLI = 0.984, RMSEA = 0.078, SRMR = 0.076). Significant correlations were found between the FoP-Q-SF scores and related anxiety measures, including the HADS-D, HADS-A and EORTC QLQ-C30 emotional and total scores (0.395–0.578, p < 0.01). The known-groups validity analysis revealed that the FoP-Q-SF scores were higher among female cancer patients (p < 0.001), which was consistent with the findings of previous studies, while no significant associations were observed with cancer patients’ age, marital status, perceived income, educational status or psychiatric history. The FoP-Q-SF is a valid and reliable tool for assessing the FoP among Turkish cancer patients, which renders it suitable for clinical and research applications in this population.
13 December 2025 in BMC Cancer
Immune checkpoint inhibitors (ICIs) improve the outcomes across solid tumours, although they can cause severe immune-related adverse events (irAEs). Due to
11 January 2026 in Expert Review of Anticancer Therapy
Immune checkpoint inhibitors (ICIs) improve survival in solid tumors but can cause immune-related adverse events (irAEs) that often require systemic steroids. The impact of steroid dose and timing on ICI efficacy remains unclear. We conducted a single-center retrospective study of 466 patients with metastatic solid tumors treated with ICIs between June 2016 and September 2024. Steroids for irAEs were categorized as high dose (≥1 mg/kg prednisolone-equivalent) or low dose (≤0.5 mg/kg). Overall survival (OS), progression-free survival (PFS), and post-irAE OS/PFS were evaluated. IrAEs occurred in 182 (39.1%) patients, and 81 (17.4%) received systemic steroids. IrAE occurrence was associated with reduced mortality risk. Among patients with irAEs, steroid use increased mortality (p = 0.035) without significantly affecting PFS. High-dose steroids were linked to worse post-irAE OS (p = 0.002) and PFS (p = 0.034), while low-dose steroids showed no detrimental effect. Early initiation ( < 2 months) of high-dose steroids demonstrated the strongest negative association. High-dose steroids, particularly when started early, are associated with significantly worse survival after irAEs in metastatic solid tumors. These findings support managing irAEs with the lowest effective steroid dose and encourage exploration of steroid-sparing strategies. Subtype-specific analyses were limited by small sample sizes and should be interpreted cautiously.